MAG and Guillain-Barre syndrome: On the other hand, rituximab, an anti-CD20 mAb increasingly used in chronic dysimmune neuropathies, including anti-MAG (myelin-associated glycoprotein) neuropathy, paranodopathies and refractory CIDP (chronic inflammatory demyelinating polyneuropathy), has not been the subject of research in GBS, with one anecdotal case report suggesting benefit [94] and others raising the possibility of rituximab contributing to the onset of GBS [95, 96].